• News

"Research Shifting to Explore Combinations for Treatment of Advanced HCC, Expert Says" - Nichole Tucker

  • Targeted Oncology
  • New York, NY
  • (August 08, 2019)

Now that several single-agent tyrosine kinase inhibitors (TKIs) have been ingrained as standards of care treat patients with hepatocellular carcinoma (HCC) in the first- and second-line settings, the next wave of research is shifting and single agents will become a thing of the past, according to Josep Llovet, MD, PhD, founder and director of the Liver Cancer Program at the Icahn School of Medicine at Mount Sinai. He added, “Now, we're finishing a period of single-agent [therapies] and moving to the next phase, which is combination therapies…. I think we're moving to the next 5 years where we will see combinations of agents in frontline and second line.”

— Josep M. Llovet, MD, PhD, Director, Founder, The Liver Cancer Program, Professor, Medicine, Icahn School of Medicine at Mount Sinai

Learn more